Pricing

Ocuphire Pharma Inc (OCUP)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Mina P. Sooch
Employees:
9
37000 GRAND RIVER AVE., SUITE 120, FARMINGTON HILLS, MI, 48335
248-681-9815
Stock Split History
DateRatio
2005-05-16 1:1
2017-05-05 1:10
2019-04-12 1:12
2020-11-06 1:4
Ocuphire Pharma, Inc. focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, which is in Phase III clinical trial for dim light or night vision disturbances. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available